Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Surgery Partners (SGRY) EBITDA Margin (2016 - 2025)

Surgery Partners' EBITDA Margin history spans 12 years, with the latest figure at 12.45% for Q4 2025.

  • For Q4 2025, EBITDA Margin fell 225.0% year-over-year to 12.45%; the TTM value through Dec 2025 reached 11.77%, up 57.0%, while the annual FY2025 figure was 16.92%, 107.0% up from the prior year.
  • EBITDA Margin for Q4 2025 was 12.45% at Surgery Partners, down from 12.87% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 18.81% in Q4 2021 and bottomed at 6.96% in Q1 2023.
  • The 5-year median for EBITDA Margin is 12.44% (2022), against an average of 12.35%.
  • The largest annual shift saw EBITDA Margin surged 764bps in 2021 before it crashed -988bps in 2023.
  • A 5-year view of EBITDA Margin shows it stood at 18.81% in 2021, then decreased by -29bps to 13.32% in 2022, then grew by 4bps to 13.79% in 2023, then rose by 7bps to 14.7% in 2024, then dropped by -15bps to 12.45% in 2025.
  • Per Business Quant, the three most recent readings for SGRY's EBITDA Margin are 12.45% (Q4 2025), 12.87% (Q3 2025), and 13.52% (Q2 2025).